Compare RZLT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | ESPR |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.4M | 793.7M |
| IPO Year | 2011 | 2013 |
| Metric | RZLT | ESPR |
|---|---|---|
| Price | $3.05 | $2.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $9.17 | $7.20 |
| AVG Volume (30 Days) | 2.4M | ★ 2.9M |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.32 | ★ 86.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $332,314,000.00 |
| Revenue This Year | N/A | $27.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 185.66 |
| 52 Week Low | $1.07 | $0.73 |
| 52 Week High | $11.46 | $4.18 |
| Indicator | RZLT | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 31.01 |
| Support Level | $2.80 | $2.66 |
| Resistance Level | $4.21 | $2.94 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 10.78 | 4.09 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.